Browse DGKI

Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus.
Domain PF12796 Ankyrin repeats (3 copies)
PF00130 Phorbol esters/diacylglycerol binding domain (C1 domain)
PF00609 Diacylglycerol kinase accessory domain
PF00781 Diacylglycerol kinase catalytic domain
Function

-

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0006836 neurotransmitter transport
GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway
GO:0007265 Ras protein signal transduction
GO:0007269 neurotransmitter secretion
GO:0007270 neuron-neuron synaptic transmission
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0007611 learning or memory
GO:0007612 learning
GO:0023061 signal release
GO:0030168 platelet activation
GO:0030258 lipid modification
GO:0034260 negative regulation of GTPase activity
GO:0035249 synaptic transmission, glutamatergic
GO:0042391 regulation of membrane potential
GO:0044708 single-organism behavior
GO:0046578 regulation of Ras protein signal transduction
GO:0046579 positive regulation of Ras protein signal transduction
GO:0046834 lipid phosphorylation
GO:0046958 nonassociative learning
GO:0046959 habituation
GO:0048167 regulation of synaptic plasticity
GO:0050804 modulation of synaptic transmission
GO:0050805 negative regulation of synaptic transmission
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0050890 cognition
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051057 positive regulation of small GTPase mediated signal transduction
GO:0051346 negative regulation of hydrolase activity
GO:0051966 regulation of synaptic transmission, glutamatergic
GO:0060078 regulation of postsynaptic membrane potential
GO:0060079 excitatory postsynaptic potential
GO:0060292 long term synaptic depression
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099565 chemical synaptic transmission, postsynaptic
GO:0099643 signal release from synapse
GO:1900452 regulation of long term synaptic depression
Molecular Function GO:0004143 diacylglycerol kinase activity
GO:0004857 enzyme inhibitor activity
GO:0005095 GTPase inhibitor activity
GO:0017016 Ras GTPase binding
GO:0030695 GTPase regulator activity
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0008021 synaptic vesicle
GO:0030133 transport vesicle
GO:0030424 axon
GO:0030425 dendrite
GO:0032045 guanyl-nucleotide exchange factor complex
GO:0033267 axon part
GO:0043025 neuronal cell body
GO:0043197 dendritic spine
GO:0043679 axon terminus
GO:0044297 cell body
GO:0044306 neuron projection terminus
GO:0044309 neuron spine
GO:0048786 presynaptic active zone
GO:0060076 excitatory synapse
GO:0070382 exocytic vesicle
GO:0097060 synaptic membrane
GO:0098793 presynapse
GO:0098794 postsynapse
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04070 Phosphatidylinositol signaling system
hsa00561 Glycerolipid metabolism
hsa00564 Glycerophospholipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-114508: Effects of PIP2 hydrolysis
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DGKI and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DGKI in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DGKI in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1470.614
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1450.778
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3690.364
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.220.014
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2810.354
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.150.454
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1020.844
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2630.749
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0760.926
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.750.246
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3840.643
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0750.626
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DGKI in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.86.880.247
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.86.880.252
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.829.4-24.60.0712
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.550-37.50.245
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.27.45.80.69
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.77.7150.377
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DGKI. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DGKI. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DGKI.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DGKI. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DGKI expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DGKI and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDGKI
Namediacylglycerol kinase, iota
Aliases DGK-IOTA; DAG kinase iota; diglyceride kinase iota; Diacylglycerol kinase iota
Chromosomal Location7q32.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DGKI collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.